Thursday, February 9, 2012

FDA pulls Impax generic antibiotic as it approves Mylan dose

Impax Laboratories Inc. lost market exclusivity for its generic rendition of the antibiotic Doryx as competitor Mylan Inc. won approval for its version.
The Hayward-based drug maker (NASDAQ: IPXL) said Thursday that the Food and Drug Administration has “forfeited” Impax’s exclusivity for its 150-milligram generic Doryx.

No comments:

Post a Comment